31 December 2015 - The Transparency Commission will consider the reimbursement of adalimumab (Humira), delamanid (Deltyba), panobinostat lactate (Farydak), lenalidomide (Revlimid) and sacubitril with valsartan (Entresto).

For more details, go to: http://www.has-sante.fr/portail/upload/docs/application/pdf/2015-12/ordre_du_jour_ct_06012016_internet.pdf [French]